MedPath

FLIO and the Influence of Oral Lutein Supplementation on Macular Pigment

Phase 4
Completed
Conditions
Age Related Macular Degeneration
Interventions
Drug: NUTROF TOTAL
Registration Number
NCT04761341
Lead Sponsor
Insel Gruppe AG, University Hospital Bern
Brief Summary

To investigate the effects of lutein supplementation on macular pigment density using FLIO and MPOD measurements in patients with age-related macular degeneration and healthy subjects over a course of 6 months.

Detailed Description

The human macula is a small area of the retina responsible for central vision. The yellow macular pigment contains three carotenoids, lutein ((3R,3'R,6'R)-lutein), zeaxanthin ((3R,3'R)-zeaxanthin), and meso-zeaxanthin ((3R,3'S;meso)-zeaxanthin). The human body is unable to synthesize lutein and zeaxanthin, thus needs to be obtained from dietary sources such as green leafy vegetables and supplements. The function of the macular pigment is to act as a filter by absorbing blue light that may attenuate photochemical damage of the retina. Furthermore, it protects against light induced oxidative damage by functioning as an antioxidant; scavenging free radicals. A growing body of evidence has established a link between the concentrations of the macular pigment carotenoids, the macular pigment optical density (MPOD) levels, visual performance and the risk of macular degeneration.

The ability of the macular pigment to absorb or filter blue light can be measured as macular pigment optical density (MPOD), which is directly related to the quantity of lutein and zeaxanthin in the macula. Furthermore, preliminary data showed that macular pigment can be evaluated using Fluorescence lifetime imaging ophthalmoscopy (FLIO). In a previous study the investigators have shown that FLIO provides contrast for macular pigment in patients with AMD and healthy subjects.

The purpose of this study is to investigate the effects of oral lutein supplementation on macular pigment density using FLIO and MPOD measurements in healthy subjects and patients with age-related macular degeneration (AMD) over a course of 6 months. Furthermore, the investigators will assess whether compositional and functional alterations of the gut metagenome may be related to age-related macular degeneration, and the effects of lutein supplementation on the gut. In addition, to blood samples, stool samples will be analysed accordingly to the currently running study on "The role of the gut metagenome on the development of ophthalmic diseases" ClinicalTrials.gov Identifier: NCT02438111. Faecal analyses will provide insight to how oral lutein supplementation effects the gut microbiota and how it is influenced by serum lutein Levels.

Objective is to investigate the effects of lutein supplementation on macular pigment density using FLIO and MPOD measurements in patients with age-related macular degeneration and healthy subjects over a course of 6 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • Subject must be willing to give written informed consent
  • Probands 18 years of age or greater
  • Both eyes will be assessed in the study
Exclusion Criteria
  • Opacities of ocular media excluding detailed observation of the retina
  • Gastrointestinal diseases that could cause disturbance of dietary absorption
  • History of lutein supplementation
  • Allergy to lutein and zeaxanthin
  • Missing compliance

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
AMDNUTROF TOTAL-
healthy controlNUTROF TOTAL-
Primary Outcome Measures
NameTimeMethod
Macular pigment screener (MPS) II6 Months

Screening Method to detect changes in macular pigment optic Density using heterochromatic flicker photometry

Fluorescence Lifetime Imaging Ophthalmoscopy (FLIO)6 Months

Retinal Autofluorescence lifetimes

MPOD (macular pigment optical Density)6 Months

Method to detect changes in macular pigment optic Density using dual wavelength autofluorescence

Secondary Outcome Measures
NameTimeMethod
Contrast sensitivity6 Months

Using Pelli-Robson charts

Visual acuity6 Months

Visual acuity using ETDRS charts

Serum Lutein concentration6 Months
Stool Analysis namely taxonomic and functional characterization of gut microbiota6 Months

Trial Locations

Locations (1)

Department of Ophthalmology, Inselspital, Bern University Hostpital, University of Bern, Bern, Switzerland

🇨🇭

Bern, Switzerland

© Copyright 2025. All Rights Reserved by MedPath